Edwards Lifesciences EW Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.09B+2.3% | $1.07B-21.5% | $1.36B-67.1% | $4.14B-0.8% | $4.18B+0.1% | ||
| $160.9M+2.7% | $156.6M+0.1% | $156.5M+3.1% | $151.8M-1.0% | $153.3M-1.2% | ||
| $163.3M+3.3% | $158.1M+5.0% | $150.6M-0.6% | $151.5M-4.1% | $157.9M-2.7% | ||
| -$51M+2.9% | -$52.5M-641% | $9.7M-80.9% | $50.9M-72.7% | $186.7M-27.1% | ||
| $151.4M-61.7% | $395.1M+74.5% | $226.4M+650% | $30.2M-61.4% | $78.3M-15.4% | ||
| —— | —— | —— | —— | $46.8M+109% | ||
| —— | —— | -$687.9M-11,559% | -$5.9M-105% | $127.6M+168% | ||
| $1.36B-14.8% | $1.6B— | —— | —— | —— | ||
| $269.1M+3.4% | $260.2M+22.4% | $212.6M+2.7% | $207M-14.8% | $243.1M-3.7% | ||
| $71.1M+9.7% | $64.8M-16.1% | $77.2M-24.8% | $102.6M— | —— | ||
| $3.1B+0.2% | $3.09B+16.8% | $2.65B+22.7% | $2.16B+40.7% | $1.53B+70.3% | ||
| $56.9M-8.4% | $62.1M+1.3% | $61.3M-4.7% | $64.3M-2.4% | $65.9M+14.6% | ||
| -$891M-25.0% | -$712.9M— | —— | —— | —— | ||
| $1.06B+18.3% | $893.4M-6.2% | $952.9M-24.7% | $1.27B-10.8% | $1.42B+22.3% | ||
| -$1.2B-19.1% | -$1.01B-1.1% | -$998.1M+19.2% | -$1.23B+7.3% | -$1.33B-31.6% | ||
| -$22.4M+53.6% | -$48.3M-1,889% | $2.7M+106% | -$47.8M-527% | $11.2M-71.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$84.6M+36.2% | -$132.5M-9.3% | ||
| $83.9M-28.7% | $117.6M-27.3% | $161.7M-39.4% | $266.7M-14.5% | $311.9M-3.6% | ||
| -$89.8M-17.4% | -$76.5M-3.1% | -$74.2M0.0% | -$74.2M-8.6% | -$68.3M-85.6% | ||
| $43M+81.4% | $23.7M— | —— | —— | —— | ||
| $26.3M+1.5% | $25.9M+1.6% | $25.5M+1.2% | $25.2M-3.8% | $26.2M-5.8% | ||
| —— | —— | —— | -$19.5M-19.6% | -$16.3M-23.5% | ||
| $22.1M-12.0% | $25.1M-49.4% | $49.6M-5.3% | $52.4M+36.5% | $38.4M-16.9% | ||
| $8.3M+5.1% | $7.9M-53.5% | $17M— | —— | —— | ||
| $43M-0.7% | $43.3M-18.0% | $52.8M+4.3% | $50.6M-12.6% | $57.9M+26.1% | ||
| $178.3M+26.5% | $140.9M+9.7% | $128.4M+10.6% | $116.1M+48.3% | $78.3M+24.3% | ||
| $2.7B-4.2% | $2.82B+18.8% | $2.37B+28.0% | $1.85B+25.9% | $1.47B+83.8% | ||
| -$2.8M+26.3% | -$3.8M-443% | -$700K+91.8% | -$8.5M-270% | -$2.3M+28.1% | ||
| $193.1M+10.9% | $174.1M+2.2% | $170.4M+0.1% | $170.2M+1.7% | $167.3M-6.8% | ||
| —— | —— | —— | —— | -$3.89B+0.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.06B0.0% | ||
| $1.09B-18.4% | $1.34B— | —— | —— | —— | ||
| $1.09B-18.4% | $1.34B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Edwards Lifesciences generate?
- Edwards Lifesciences (EW) generated $1.4B in operating cash flow over the trailing twelve months.
- What is Edwards Lifesciences's free cash flow?
- After $269.1M of capital expenditures, Edwards Lifesciences's free cash flow was $1.1B over the trailing twelve months, up 57.5% year over year.
- Where does Edwards Lifesciences's cash flow data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
